This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
VAPO Overzicht aandelen
A medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 0/6 |
| Dividenden | 0/6 |
Vapotherm, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$2.17 |
| 52 Week Hoogtepunt | US$3.44 |
| 52 Week Laag | US$0.70 |
| Bèta | -1.1 |
| 11 maand verandering | 0.59% |
| 3 maanden verandering | 2.60% |
| 1 Jaar Verandering | -22.22% |
| 33 jaar verandering | -98.97% |
| 5 jaar verandering | -97.04% |
| Verandering sinds IPO | -98.30% |
Recent nieuws en updates
Recent updates
Vapotherm announces $23M private placement
Feb 08Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02M
Nov 02Vapotherm draws downgrade at William Blair after 2Q results
Aug 04Vapotherm: Out Of Air
May 11Is Vapotherm (NYSE:VAPO) Using Too Much Debt?
Jan 24
Vapotherm: Hardly Breathing Room
Jul 11Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?
May 10Vapotherm reports Q1 results
May 05The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares
Mar 12Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last Year
Mar 11Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?
Jan 19
Vapotherm guides Q4 revenue above consensus, ~212% Y/Y growth
Jan 13Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On Shares
Dec 14Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%
Dec 11Vapotherm shares +9% on higher Q4 guidance
Dec 01Vapotherm: The Game Has Completely Changed
Nov 13Rendement voor aandeelhouders
| VAPO | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 0.5% | -0.6% | -0.4% |
| 1Y | -22.2% | 22.6% | 34.1% |
Rendement versus industrie: VAPO underperformed the US Medical Equipment industry which returned 18.6% over the past year.
Rendement versus markt: VAPO underperformed the US Market which returned 27.6% over the past year.
Prijsvolatiliteit
| VAPO volatility | |
|---|---|
| VAPO Average Weekly Movement | 1.7% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: VAPO's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: VAPO's weekly volatility has decreased from 27% to 2% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1993 | 182 | Joe Army | www.vapotherm.com |
Vapotherm, Inc. Samenvatting
| VAPO fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$13.61m |
| Inkomsten(TTM) | -US$54.42m |
| Inkomsten(TTM) | US$70.92m |
0.2x
P/S-verhouding-0.2x
Koers/WinstverhoudingIs VAPO overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| VAPO resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$70.92m |
| Kosten van inkomsten | US$37.71m |
| Brutowinst | US$33.21m |
| Overige uitgaven | US$87.63m |
| Inkomsten | -US$54.42m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -8.71 |
| Brutomarge | 46.82% |
| Nettowinstmarge | -76.74% |
| Schuld/Eigen Vermogen Verhouding | -145.6% |
Hoe presteerde VAPO op de lange termijn?
Bekijk historische prestaties en vergelijking